BioRestorative Therapies

07/09/2026

Today we’re featuring our Director of Research and Development, Dr. Michael Joyce.

At , Dr. Joyce leads the advancement of our clinical programs and next-generation platform. His experience bridging fundamental science with translational development strengthens BioRestorative's ability to generate compelling preclinical and clinical data, expand its intellectual property portfolio, and accelerate the development of novel therapies and regenerative products.

&D

07/02/2026

Wishing everyone celebrating America250 a joyful and safe holiday weekend from all of us at BioRestorative Therapies!

07/01/2026

Featuring Vice President of Biocosmeceuticals, Zachary Smith!

Mr. Smith is an accomplished sales and commercial leadership executive with more than 16 years of experience across medical aesthetics, biologics and capital equipment markets. He will lead revenue growth initiatives across professional aesthetics, regenerative physician channels, strategic partnerships and key accounts, with a focus on driving commercial ex*****on, expanding customer acquisition and building long-term revenue-generating relationships across the Company’s growing platform.

Learn more: https://bit.ly/4vWvA3V

06/29/2026

New findings presented at suggest that therapies like tirzepatide may do more than support weight loss. Researchers reported evidence that these therapies may also activate brown adipose tissue (BAT), a type of fat involved in energy expenditure and metabolic regulation.

For , this research highlights an exciting area of alignment with our work.

If GLP-1s can help activate brown adipose tissue, it raises an important possibility: could combining brown adipose with GLP-1s create a more targeted approach to treating metabolic and obesity-related disorders?

By pairing therapies designed to influence BAT biology with established metabolic treatments, future approaches may have the potential to go beyond weight loss alone and address underlying metabolic function.

Learn more: https://bit.ly/4g7LNPl

Endocrine Society

Tirzepatide doesn’t just help people lose weight; it also activates brown adipose tissue, representing a major milestone in obesity research, according to a study being presented Monday at ENDO 2026, the Endocrine Society’s annual meeting in Chicago, Ill.

06/25/2026

announces the successful completion of manufacturing for its BRTX-100 Phase 2 , marking a key milestone in the development of its lead candidate and underscoring the strength of the Company’s vertically integrated platform.

Manufacturing of the BRTX-100 clinical supply was completed in the Company’s cGMP ISO-7 certified facility, supporting ongoing clinical development for the treatment of chronic lumbar disc disease.

Full press release here: bit.ly/4oJYCBv

06/23/2026

is actively advancing an integrated platform designed to address significant unmet needs across healthcare and aesthetics.

has multiple value creation catalysts ahead, including clinical, regulatory, commercialization, and partnership milestones. The vertical integration positions the company at the intersection of regenerative therapeutics and biologics commercialization as we continue to build toward long-term growth across multiple pathways.

06/18/2026

announces the appointment of Zachary Smith as Vice President of its Biocosmeceuticals Division, further strengthening the Company’s commercial leadership team as it expands its presence within the regenerative aesthetics and advanced skincare market.

Mr. Smith will lead revenue growth initiatives across professional aesthetics, regenerative physician channels, strategic partnerships and key accounts, with a focus on driving commercial ex*****on, expanding customer acquisition and building long-term revenue-generating relationships across ’s growing platform. He will oversee domestic and international sales channel expansion, strategic account development, sales forecasting, pipeline development, territory growth initiatives and customer retention programs designed to support long-term recurring revenue growth.

Full press release here: bit.ly/4vWvA3V

06/16/2026

Today we’re featuring ’ Chief Financial Officer, Robert Kristal! Robert brings an extensive array of strategic and financial markets experience to the team, including a background in advising global public life sciences companies in corporate finance, operations management systems, and strategic collaborations.

An experienced and versatile Wall Street and Bay St. professional of over 25 years, Robert has built teams in both institutional sales and equity research at firms which have developed a notable presence in healthcare research and capital market activities.

06/11/2026

The team recently visited IPS Labs to learn more about the science and expertise behind successful formulation development.

Thank you to the full IPS team for providing an in-depth look at their facility, technologies, and approach to innovation. We appreciate the opportunity to connect with industry experts who continue to advance the field through technical excellence and scientific expertise!

06/09/2026

: ’ fully enrolled, randomized, double-blind, sham-controlled Phase 2 study in chronic lumbar disc disease (cLDD) has completed treatment administration in 99 patients, continuing Phase 3 readiness activities following U.S. Food and Drug Administration Type B meeting alignment.

This key development advances the company’s lead regenerative spine program toward topline data in 2027.

Learn more in the full press release: https://bit.ly/4dxJoMf